Avelas’ mission is to empower physicians to operate once by improving surgery through real-time cancer detection with AVB-620.

Surgery is often the first-line treatment for cancer patients. However, despite advances in radiologic and surgical techniques, surgeons continue to rely mainly on eyesight and palpation to determine the extent of cancer. Too frequently, surgeons will not know where the tumor begins and ends while operating. This uncertainty can lead to incomplete detection and removal of cancer, which most often is determined a week post-surgery when histopathology reports are received. 

The presence of residual cancer after a surgery is referred to as “positive margins,” and is increasingly recognized as a significant unmet need across numerous cancer surgeries. For example, patients with positive margins in breast cancer are more than 2x likely to have cancer recurrence. Therefore, many physicians elect to re-operate on patients. It is estimated that anywhere from 20-40% of women undergoing a primary lumpectomy for breast cancer have to undergo a second surgery for complete cancer removal.

Avelas has demonstrated that intraoperative imaging with AVB-620 can detect ~80% of the positive or close margins that otherwise would be missed with current best practices. Ultimately, it is our goal to create better outcomes for patients with AVB-620.